Deverra Therapeutics

SEATTLE, WA · Founded 2019 · CIK 0001822782 · Biotech · Private

Universal donor cell therapies for cancer and other diseases

devetrx.com →
Grants
—
No SBIR or STTR on record
Sector median: 1
Raised
$2.5M
2 Form D · Sep 2023
37 months since last filing
Contracts
—
No federal contracts on record
Patents
12
1 granted · 11 pending
Sector median: 2

Capital Timeline

Federal above the line · equity below · node area scaled to amount
Capital and federal award history
DateEventSourceAmount
Private capital raisedForm D · SEC$75,000
Private capital raisedForm D · SEC$2,388,889
Form D · SEC

Peer position

Biotech · 4373 companies · ranked on federal contract value
Biotech companies ranked by federal contract value
#CompanyContractsDisclosed equity
2532STEMLINE THERAPEUTICS INC—$2.6M
2533Form Bio—$16M
2534A2 THERAPEUTICS, INC.——
2535Deverra Therapeutics—$2.5M
2536ELIAS Animal Health, LLC—$2.4M
2537BIOIO, LLC——
2538EIKONIZO THERAPEUTICS, INC.—$2.4M

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Founders & Team

From Form D filings · 2 related persons
  • Colleen DelaneyExecutive Officer
  • Michael YurkowskyDirector · Executive Officer

Patents

USPTO · 1 granted of 12
  • Nk Cell Compositions And Preparations For Immunotherapy And Methods For Their Productiongranted
  • Compositions And Methods For Culturing Hematopoietic Stem And Progenitor Cellsapplication
  • Compositions And Methods For Improving Treatment Outcomes For Patients Having Hematological Malignancies Using An Expanded Stem Cell Productapplication
  • Nk Cell Composition And Preparations For Immunotherapy And Methods For Their Productionapplication
  • Compositions And Methods For Improving Treatment Outcomes For Patients Having Hematological Malignancies Using An Expanded Stem Cell Productapplication
  • NK Cell Preparations for Immunotherapyapplication
  • Compositions And Methods For Culturing Hematopoietic Stem And Progenitor Cellsapplication
  • NK Cell Preparations for Immunotherapyapplication
  • Methods For The Generation Of A Monocyte/macrophage Cell Product From Expanded Cord Blood CD34+ Hematopoietic Stem And Progenitor Cellsapplication
  • Methods For The Generation Of A Monocyte/macrophage Cell Product From Expanded Cord Blood CD34+ Hematopoietic Stem And Progenitor Cellsapplication
  • Methods For The Generation Of A Monocyte/macrophage Cell Product From Expanded Cord Blood CD34+ Hematopoietic Stem And Progenitor Cellsapplication
  • Compositions And Methods For Culturing Hematopoietic Stem And Progenitor Cellsapplication

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.